medigraphic.com
ISSN 1405-8871 (Print)

2018, Number 3

<< Back Next >>

Aten Fam 2018; 25 (3)

Clinical Features of Peritoneal Dialysis Associated to Peritonits in the Regional General Hospital No. 1 in Michoacán, México

Joaquín RIJ, Barajas GS, Corona CII, Gómez AC, Álvarez AC

Language: Spanish
References: 28
Page: 91-96
PDF size: 321.60 Kb.


Text Extraction

Objective: clinically characterize peritoneal dialysis associated to peritonitis PDAD) and identify microorganisms present in this disease. Methods: crosssectional study. From January 2013 to December 2015, information on clinical records was obtained about sociodemographic, clinical and laboratory variables, of 34 patients over 18 years old who were hospitalized with a diagnosis of continuous ambulatory peritoneal dialysis associated to peritonitis in the Regional General Hospital No.1 in Charo, Michoacán, Mexico. The data were presented at averages, standard deviation for continuous variables and frequency percentage for categorical variables. Results: the etiology of end-stage renal disease (ERD) was diabetic nephropathy in 15 patients (44.1%), unknown in 11 (32.4%), arterial hypertension in 7 (20.6%), and a Polycystic Kidney (2.9%). The isolated microorganisms were Staphylococcus epidermidis in 14 patients (41.2%), Escherichia coli in 8 (23.5%), and Enterococcus faecalis in 6 (17.6%); there was antimicrobial resistance to macrolides, ciprofloxacin, and third generation cephalosporin. 19 patients (55.9%) required hospital stay for more than seven days; 14 (41.2%) result in change of the dialytic mode, and 6 (17.6%) died. Conclusion: the pdad increases during hospitalization, morbidity and mortality in patients with erd; Staphylococcus epidermidis was the most frequently isolated organism. It is important to educate population on prevention, as well as the family physician participation who must promote a greater linkage with the second level care.


REFERENCES

  1. AS Levey, R Atkins, J Coresh, EP Cohen, AL Colins, K U Eckardt et al. Chronic kidney disease as a global public health problem: Approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007;72:247-259.

  2. usrds Annual Data Report. Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. Am J Kidney Dis [internet. Consultado el 22 de abril de 2018]. Disponible en: https://www.ajkd.org/article/S0272- 6386(15)00718-0/pdf

  3. Méndez Duran A, Ignorosa Luna MH, Pérez Aguilar G, Rivera Rodríguez FJ, Gonzalez Izquierdo J de J, Dávila Torres J. Estado actual de las terapias sustitutivas de la función renal en el Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc. 2016;54(5):588-593.

  4. Ng S, Johnson DW, Cho Y. Early Onset Peritoneal Dialysis-Related Peritonitis. J Clin Exp Nephrol. 2017;2(3):1-7.

  5. Mustafa M, Menon J, Hamed S, Illzam EM, Sharifa AM, Arif SHM. Diagnosis and Treatment of Peritonitis in Patients on Continuous Ambulatory Peritoneal Dialysis. iosr J Dent Med Sci. 2015;14(10):63-67.

  6. Kofteridis DP, Valchis A, Perakis K, Maraki S, Daphnis E, Samonis G. Peritoneal dialysis-associated peritonitis: clinical features and predictors of outcome. Int J Inf Dis 2010;14:e489-e493.

  7. Guía de práctica clínica, diagnóstico y tratamiento de la peritonitis infecciosa en diálisis peritoneal crónica en adultos, México: Secretaría de Salud; 2009.

  8. Cortés López LA, González Castillo DE, Elizalde Barrera CI, Flores Alcántar G. Elevación del fibrinógeno como marcador de riesgo de peritonitis en pacientes con enfermedad renal crónica estadio 5 k/doqui en tratamiento sustitutivo de la función renal con diálisis peritoneal. Med Int Mex. 2013;29(6):581-586.

  9. Avusula R, Shoemaker Moyle M, Pathak MB, Csongrádi É, Fülöp T. Bacterial Peritonitis Following Esophagogastroduodenoscopy in a Patient on Peritoneal Dialysis. British Journal of Medical Research. 2013;3(3):784-789.

  10. Freire Abud AC, Kusumota L, dos Santos MA, Luchetti Rodrigues FF, Coelhoo Damascenso MM, Zaneti ML. Peritonitis e infección del orificio de salida del catéter en pacientes en diálisis peritoneal en el domicilio. Rev. Latino-AM. Enfermagem. 2015;23(5):902-909.

  11. Guirao X, Arias J, Badía JM, García Rodríguez JA, Mensa J, Álvarez Lerma F, et al. Recommendations in the empiric anti-infective agents of intra-abdominal infection. Rev Esp Quimioter. 2009;22(3):151-172.

  12. Figueiredo AE, De Moraes TP, Bernardini J, Poli de Figueiredo CE, Barretti P, Olandoski M, et al. Impact of patient training patterns on peritonitis rates in a large national cohort study. Nephrol Dial Transplant. 2015;30(1):137-142.

  13. Hernández MR, Mejía Velázquez JL, Ortiz López I. Etiología de peritonitis asociada a diálisis peritoneal continua ambulatoria en urgencias. Arch Med Urgenc México. 2013;5(1):5-10.

  14. Afrashtehfar cdm, Mastache Gutiérrez A, Afrashtehfar KI, Díaz Casales LA, Solís Bazaldúa M. Manifestaciones clínicas y bacteriológicas de la peritonitis asociada con la diálisis peritoneal. Rev Med Inst Mex Seguro Soc. 2014;52(1):84-90.

  15. Dante Amato, Cleto Alvarez Aguilar, Rutila Castañeda Limones, Ernesto Rodríguez, Marcela Avila Diaz, Francisco Arreola et al. Prevalence of chronic kidney disease in an Mexican urban population. Kidney Int. 2005; 68 (Suppl 97):S11-S17.

  16. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. J Renal Inj Prev. 2014;3(4):109-110.

  17. Stevens G, Dias RH, Tomas KJ, Rivera JA, Carvalho N, Barquera S, et al. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. Plos Med. 2008;5(6):e125.

  18. Gutierrez G, Pérez Cuevas R, Levy S, Reyes H, Acosta B, Cantón SF, et al. Strengthening preventive care programs: a permanent challenge for healthcare systems; lessons from PrevenIMSS México. BMC Public Health 2010;10:417.

  19. Programa Institucional de Prevención y Atención al Paciente Diabético Diabetimss. Instituto Mexicano del Seguro Social 2009.

  20. Barretti P, Pereira Doles JV, Goncalves Pinotti D, Pulocci El Dib R. Evidence-based medicine: An update on treatments for peritoneal dialysis-related peritonitis. World J Nephrol 2015;4(2):287-294.

  21. Philip Kam Tao Li, Cheuk Chun Szeto, Berth Piraino, Javier de Arteaga, Stanley Fan, Ana E. Figueiredo, et al. ispd Guidelines/recomendations 2016 Update on prevention and treatment. Perit Dial Int 2016;36(5):481-508.

  22. Saxena R, West C. Peritoneal dialysis: A primary care perspective. J Am Board Fam Med. 2006;19:380-389.

  23. Campbell DJ, Craig JC, Mudge DW, Brown FG, Wong G, Tong A. Patient’s perspective on the pevention and treatment of peritonitis in peritoneal dialysis: A semi-structured interview study. Perit Dial Int. 2016;36:631-639.

  24. Brown F, Gulyani A, McDonald S, Hurst K. Chapter 6: peritoneal dialysis. anzdata 2012 Annual Report. 35th ed. 2012 [internet. Consultado el 7 de marzo de 2018] Disponible en: http:// www.anzdata.org.au/anzdata/AnzdataReport/35t hReport/2012c06_peritoneal_v3.pdf

  25. Nakao M, Yamamoto I, Maruyama Y, Nakashima A, Matsuo N, Tanno Y, et al. 33Years of Peritoneal Dialysis-Associated Peritonitis: A Single-Center Study in Japan. Ther Apher Dial. 2016;20(1):60-65.

  26. Montelli AC, Sadatsune T, Mondelli AL, Cunha MLRS, Caramori JCT, Barretti P, et al. Frequency and antimicrobial susceptibility of bacterial agents causing peritoneal dialysis-peritonitis in a Brazilian single center over 20 years. Cogent Mediicne. 2016;3:122246.

  27. Fan X, Huang R, Wang J, Ye H, Guo Q, Yi C, et al. Risk factors for the first episode of peritonitis in Southern Chinese continuous ambulatory peritoneal dialysis patients. PloS One. 2014;9(9):1-8.

  28. Zelenitsky SA, Howarth J, Lagacé-Wiens P, Sathianathan C, Ariano R, Davis C, et al. Microbiological trends and antimicrobial resistance in peritoneal dialysis-related peritonitis, 2005-2014. Perit Dial Int. 2017;37(2):170-176.




2020     |     www.medigraphic.com